JPS5959628A - Carcinostatic agent - Google Patents
Carcinostatic agentInfo
- Publication number
- JPS5959628A JPS5959628A JP57169994A JP16999482A JPS5959628A JP S5959628 A JPS5959628 A JP S5959628A JP 57169994 A JP57169994 A JP 57169994A JP 16999482 A JP16999482 A JP 16999482A JP S5959628 A JPS5959628 A JP S5959628A
- Authority
- JP
- Japan
- Prior art keywords
- activity
- catalase
- cancer
- growth
- carcinostatic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003327 cancerostatic effect Effects 0.000 title abstract 4
- 102000016938 Catalase Human genes 0.000 claims abstract description 33
- 108010053835 Catalase Proteins 0.000 claims abstract description 33
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052748 manganese Inorganic materials 0.000 claims abstract description 6
- 229910052742 iron Inorganic materials 0.000 claims abstract description 5
- 239000004006 olive oil Substances 0.000 claims abstract description 4
- 235000008390 olive oil Nutrition 0.000 claims abstract description 4
- 235000019441 ethanol Nutrition 0.000 claims abstract description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 5
- 239000011572 manganese Substances 0.000 claims description 5
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 3
- 241000270878 Hyla Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 45
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 abstract description 12
- 230000005907 cancer growth Effects 0.000 abstract description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000006035 Tryptophane Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229960004799 tryptophan Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 15
- 230000012010 growth Effects 0.000 description 15
- 108010044936 indoleacetic acid oxidase Proteins 0.000 description 9
- 208000014018 liver neoplasm Diseases 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 7
- 108700016257 Tryptophan 2,3-dioxygenases Proteins 0.000 description 7
- 201000007270 liver cancer Diseases 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 5
- 235000011957 flavonols Nutrition 0.000 description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 150000007946 flavonol Chemical class 0.000 description 3
- 235000008777 kaempferol Nutrition 0.000 description 3
- 229910001437 manganese ion Inorganic materials 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 2
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002216 flavonol derivatives Chemical class 0.000 description 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 1
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
本薬剤は高等植物の体内に普遍的に存在している生長制
御のしくみを癌の生長制御に応用したものであって、ケ
ンフェロール型芳香族炭化水素とカタラーゼを主要構成
要素に補助因子として鉄とマンガンを微量、添加したも
のである３、本薬剤が゛制癌剤として動物の、癌の治療
に使用されるだめの理論的根拠は以下に詳述する小論に
よっている。[Detailed Description of the Invention] This drug applies the growth control mechanism that exists universally in the bodies of higher plants to the growth control of cancer, and uses kaempferol-type aromatic hydrocarbons and catalase as main agents. It contains small amounts of iron and manganese as co-factors.3 The rationale for this drug to be used as an anti-cancer drug in the treatment of cancer in animals is based on the essay detailed below. .
すなわち発癌の直接の原因となっている物質は高等動物
の体内に存在する植物の生長ホルモン５−ヒドロキシイ
ンドール酢酸（略称５−０１−Ｉ Ｉ Ａ Ａ ）であ
り、その自律的生長も宿主生体からの５−０ＨＩＡＡの
供給によって維持されている。ために癌の生長は植物体
内に存在する生長制御のしくみを応用することによって
抑制せられる０、−カタラーゼ活性上昇法−
癌組織が示す生化学的特徴の一つに各種酵素活性の異常
がある。中でもカタラーゼとトリプトファンピロラーゼ
物の種類に関係のない共通の現象であると考えられてい
る。そのカタラーゼの活性についてグＩＪ−ンスタイン
の研究ではマウスの腹または尾部に癌を移植し肝カタラ
ーゼ活性を測定すると癌の発育に伴って肝カタラーゼ活
性は低下し癌を移植した尾部を切断すると活性は回復す
るという，。In other words, the substance that directly causes carcinogenesis is the plant growth hormone 5-hydroxyindoleacetic acid (abbreviated as 5-01-IIA) that exists in the bodies of higher animals, and its autonomous growth is also dependent on the host organism. It is maintained by a supply of 5-0 HIAA. Therefore, cancer growth can be suppressed by applying the growth control mechanism that exists within the plant body. . Among them, catalase and tryptophan pyrrolase are thought to be a common phenomenon unrelated to the type of substance. Regarding the activity of catalase, research by Guinstein found that when cancer was transplanted into the belly or tail of a mouse and liver catalase activity was measured, liver catalase activity decreased as the cancer grew, and when the tail where the cancer was transplanted was cut off, the activity decreased. It is said that he will recover.
次にトリプトファンピロラーゼ活性ニついてはある研究
によるとアゾ色素やエチオニンで誘発された原発肝癌で
はトリプトファンピロラーゼ活性は低く、緩慢な成長速
度を示す移植肝癌では低くない、丑だ極端に成長速度の
速いノビコツ肝癌や極端に成長速度の遅いモーリス５１
２６肝癌ではｌ・リプトファンピロラーゼ活性が欠除し
ているという。これらの事実を要約すると「癌の成長□
は組織内のカタラーゼ・トリプトファンピロラーゼの活
性の大きさと反比例しており成長の小さいときには二つ
の酵素活性は大きく癌の成長が大きくなるにつれて活性
が低く小さくなる。」と云い表わすことができる。この
活性型は植物体内に存在するＩＡＡ酸化酵素の活性（注
１）と一致しており癌ではカタラーゼとトリプトファン
ピロラーゼがＩＡＡ酸化酵素の役割を果していると考え
られる。Next, regarding tryptophan pyrrolase activity, one study found that tryptophan pyrrolase activity is low in primary liver cancers induced with azo dyes or ethionine, but not in transplanted liver cancers, which show a slow growth rate, but is not low in transplanted liver cancers, which grow at an extremely fast rate. Morris 51 with Nobikotsu liver cancer and extremely slow growth rate
26 Liver cancer is said to lack l-liptophan pyrrolase activity. To summarize these facts, “cancer growth□
is inversely proportional to the activity of catalase and tryptophan pyrrolase in the tissue, and when the growth is small, the activities of the two enzymes are high, and as the growth of the cancer increases, the activity decreases. ” can be expressed as. This active form corresponds to the activity of IAA oxidase present in plants (Note 1), and catalase and tryptophan pyrrolase are thought to play the role of IAA oxidase in cancer.
つまり癌組織に存在するＩＡＡ代謝経路（セｏトニン代
謝経路、注２）に対してトリプトファンピロラーゼはト
リプトファンにカタラーゼは５−ＱＩ−Ｉ Ｉ Ａ Ａ
にそれぞれ作用していると考えられその活性が大きいと
きにはトリプトファン・５−０ＨＩＡＡ量は減少し、反
対に活性が小さいときにはトリプトファン・５−ＯＦＩ
Ｉ Ａ Ａ Ｍ：は増大しているわけである。In other words, tryptophan pyrrolase is tryptophan and catalase is 5-QI-IIA A for the IAA metabolic pathway (seotonin metabolic pathway, note 2) that exists in cancer tissues.
When the activity is high, the amount of tryptophan/5-0HIAA decreases, and on the other hand, when the activity is low, tryptophan/5-OFI decreases.
IAAM: is increasing.
自然疵を始めとして大半の癌はこの型の活性を示すと思
われるが例外的にノビコツ肝癌やモーリス５１２５肝癌
のようにトリプトファンピロラーゼ活性の欠除したもの
がある。この場合癌の成長は、カタラーゼ活性のみで調
節が行なわれていることが予想されカタラーゼ活性の極
めて小さいものが極端に成長速度の速いノビコツ肝癌で
、カタラーゼ活性の極めて正常に近いものが極端に成長
速度の遅いモーリス５１２３肝癌であると見なすことが
できる。Most cancers, including natural lesions, are thought to exhibit this type of activity, but there are exceptions such as Novikotsu liver cancer and Morris 5125 liver cancer, which lack tryptophan pyrrolase activity. In this case, cancer growth is expected to be regulated only by catalase activity, and those with extremely low catalase activity are Novikotsu liver cancers that grow at an extremely fast rate, while those with extremely normal catalase activity have extremely high growth rates. It can be considered as slow-moving Morris 5123 liver cancer.
以上の様なカタラーゼ活性と癌の成長速度の反比例関係
は図で表現すると一層わかりやすくなる。The inversely proportional relationship between catalase activity and cancer growth rate as described above is easier to understand when expressed graphically.
（図１）図に示されている両者の関係で指摘できるのは
次の三点である。(Figure 1) The following three points can be pointed out regarding the relationship between the two shown in the figure.
（１）成長している癌はすべて正常値以下のカタラーゼ
活性を示す。(1) All growing cancers exhibit catalase activity below normal values.
（２） カタラーゼの活性が正常値になると癌の成長
速度はゼロになる即ち成長が停止する。(2) When the activity of catalase reaches a normal value, the growth rate of cancer becomes zero, that is, growth stops.
（３） カタラーゼの活性が正常値以上になると癌幻
：マイナスの成長速度を示す即ち縮小する。。(3) When the activity of catalase exceeds the normal value, cancer occurs: it exhibits a negative growth rate, that is, it shrinks. .
これらを整理すると１成長している癌のカタラーゼ活性
は低下しているがカタラーゼの活性が正常値かあるいは
正常値以上になると癌は成長を停止するか逆に縮小して
いく。」と云い表すことができる。そして次の様に結論
づけられる。［癌の成長はカタラーゼの活性を正常値以
上に上昇させることによって抑制される。」・・・・・
・・・・低下している癌のカタラーゼ活性を正常値以下
に上昇さぜるには植物体内に存在するＩＡＡ酸化酵素の
活性支配を癌に適用しなければならないが、現在明らか
にされているＩＡＡ酸化酵素の活性支配は以下の如くで
ある。To summarize these points, 1. The catalase activity of a growing cancer decreases, but when the catalase activity reaches a normal value or exceeds a normal value, the cancer stops growing or conversely shrinks. ” can be expressed as. And we can conclude as follows. [Cancer growth is inhibited by increasing catalase activity above normal levels.] ”・・・・・・
...In order to raise the declining catalase activity of cancer to below the normal value, it is necessary to apply the control of the activity of IAA oxidase, which exists in the plant body, to cancer, but it is currently clear that The activity of IAA oxidase is controlled as follows.
イ）ＩＡＡ酸化酵素の活性を支配しているのは黄色色素
フラボノールである。b) The yellow pigment flavonol controls the activity of IAA oxidase.
０）フラボノールのうちＣ環がジフェノールＪ−リのケ
ルセチンはＩＡＡ酸化酵素の活性を阻害するがモノフェ
ノール型のケンフェロールｉ、ｊ： Ｍｉ （’ＩＥ
全促進する。0) Of the flavonols, quercetin, whose C ring is diphenol J-ly, inhibits the activity of IAA oxidase, but monophenolic kaempferol i, j: Mi ('IE
Promote all.
ハ）ＩＡＡ酸化酵素はマンガンイオンやモノフェノール
類を活性発現に補助因子として要求する。c) IAA oxidase requires manganese ions and monophenols as cofactors for activity expression.
イ〜ハの事実を癌に適用する場合、■ＡＡ酸化酵素とフ
ラボノールはカタラーゼと芳香族炭化水素にそれぞれ置
き換えることができる。そして次の様に書き換えられる
。When applying facts A to C to cancer, AA oxidase and flavonol can be replaced with catalase and aromatic hydrocarbon, respectively. And it can be rewritten as follows.
イ）カタラーゼの活性を支配しているのは芳香族炭化水
素である。b) Aromatic hydrocarbons control the activity of catalase.
口）芳香族炭化水素のうちＣ３Ｎがジフェノール型のケ
ルセチンはカタラーゼの活性を阻害するがモノフェノー
ル型のケンフェロールハ活性ヲ促進する。Among aromatic hydrocarbons, quercetin, in which C3N is a diphenol type, inhibits catalase activity, but kaempferol, a monophenol type, promotes the activity.
ハ）カタラーゼはマンガンイオンやモノフェノール類を
活性発現に補助因子として要求する。c) Catalase requires manganese ions and monophenols as cofactors for its activity.
この書き換えられた事実から理角イできることは、「カ
タラーゼの活性の上昇には（ＡＩ Ｃ環がモノフェノー
ルになったケンフェロール型の芳香族炭化水素（図３）
と（Ｂ）マンガンイオンが補助因子として必要である。What can be logically concluded from this rewritten fact is that ``increasing the activity of catalase is caused by (kaempferol-type aromatic hydrocarbons in which the AIC ring becomes a monophenol (Figure 3).
and (B) manganese ions are required as cofactors.
」ということである。"That's what it means.
−投与方法−
◎ 各種ケンフェロール型芳香族炭化水素とカタラーゼ
及び補助因子としての鉄（Ｆｅ）・マンガン（Ｍ ｎ
）のエチルアルコールまたはオリーブ油溶液を癌組織の
成長部位に投与する。-Administration method- ◎ Various kaempferol-type aromatic hydrocarbons, catalase, and iron (Fe) and manganese (Mn) as cofactors.
) in ethyl alcohol or olive oil is administered to the site of cancerous tissue growth.
、注１ フラボノール＝植物の葉、花、根、茎、果実な
どの表皮細胞に多く含まれている黄色系の色素で融点２
６６℃〜６４８℃のプリズム状または知合１状の結晶で
ある。植物体内では紫外線を吸収して内部組織を保護す
る役割のほがＩＡＡ酸化酵素の活性支配にも関与してお
り倭性エントウを用いた実験ではその生長の大きさと組
織内の過酸化酵素（ＩＡＡ酸化酵素）活性の大きさが反
比例しているという即ち生長の小さいどきには過酸化酵
素の活性が大きくジベレリンを与えて生長が盛んになる
と酵素の活性が小さくなる。天然のフラボノールはその
ほとんどが水溶性の配糖体として見い出されている。。, Note 1 Flavonol = A yellowish pigment that is abundantly contained in the epidermal cells of plant leaves, flowers, roots, stems, fruits, etc., and has a melting point of 2.
It is a prismatic or 1-shaped crystal with a temperature of 66°C to 648°C. In the plant body, the role of absorbing ultraviolet rays and protecting internal tissues is also involved in controlling the activity of IAA oxidase, and experiments using Japanese peas showed that the growth size and the IAA peroxidase (IAA oxidase) in the tissues were The activity of peroxidase (oxidase) is inversely proportional, that is, when growth is low, peroxidase activity is high, and when gibberellin is provided and growth is active, the enzyme activity decreases. Most natural flavonols are found as water-soluble glycosides. .
注２ セトロニンー血液成分の一種血小板に吸収貯蔵さ
れている血管収縮物質５− ＯＨ） ’Ｊブタミンのこ
とで１９４８年ラボーうによってその存在が確認せられ
セロトニンと命名された。生理作用としては血管収縮作
用のほか消化管、神経、腎臓などの機能やアナフィラキ
シ−への関与が知られている。セロトニンは高等動物が
栄養を保持していくうえで欠かすことのできないアミノ
酸であるトリプトファンから生合成されているがその代
謝経路はインドール核の５位の位置が水酸化されている
ことを除いて植物体内に存在するインドール酢酸（略称
ＩＡＡ）の生合成経路と全く同じものである。Note 2 Serotonin - A type of blood component that is a vasoconstrictor (5-OH) that is absorbed and stored in platelets.Its name is serotonin. As for physiological effects, in addition to vasoconstriction, it is known to be involved in the functions of the gastrointestinal tract, nerves, kidneys, etc., and anaphylaxis. Serotonin is biosynthesized from tryptophan, an amino acid essential for higher animals to retain nutrients, but its metabolic pathway is similar to that in plants, except that the 5th position of the indole nucleus is hydroxylated. This is exactly the same biosynthetic pathway as indole acetic acid (abbreviated as IAA) that exists in the body.
第１図はカタラーゼ活性と癌の成長速度の反比例関係図
第２図はケンフェロールの化学構造図
第３図はケンフェロール型芳香族炭化水素の化学構造図
特許出願人 三 好 龍 男
手続補正帯（方式）
！６和５８年６月ＩＳ日
昭和５８年３月１４日差出
特許庁長官 殿
１事件の表示
昭和５７年特許願第１６９９９４号
２゜発明の名称 制 癌 剤
６補正をする者
事件との関係 特許出願人
住 所 香川県観音寺市伊吹町１０２６番地４ 補正
命令の日付
昭和５８年２月２日
５、補正の対象
願 書 ・ 明細書
６補正の内容Figure 1: Inverse relationship between catalase activity and cancer growth rate Figure 2: Chemical structure of kaempferol Figure 3: Chemical structure of kaempferol-type aromatic hydrocarbons Patent applicant: Tatsuo Miyoshi Procedural correction band (Method)! 6 June IS Date March 14, 1980 Sent Commissioner of the Japan Patent Office Tono 1 Display of case 1982 Patent Application No. 169994 2゜ Title of invention Cancer Drugs 6 Relationship with the person who amends the case Patent Applicant address 1026-4 Ibuki-cho, Kanonji-shi, Kagawa Prefecture Date of amendment order February 2, 1980 5 Application subject to amendment ・ Contents of amendment to specification 6
Claims (1)
族炭化水素 口）カタラーゼ（ｃａ−ｔａｌａｓｅ ）・・）鉄（Ｆ
ｅ） 二）マンガン（Ｍｎ） 以上イル二のエチルアルコール（ｃｔ、ｈｙｌａ］ｃｈ
ｏｌ）捷たは、オリーブ油（０１１ｖｃ０１１）溶液。[Scope of Claims] a) Kaempfero-1 type aromatic hydrocarbon) catalase (ca-talase)...) iron (F
e) 2) Manganese (Mn) Ethyl alcohol (ct, hyla)
ol) Strained or olive oil (011vc011) solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57169994A JPS5959628A (en) | 1982-09-27 | 1982-09-27 | Carcinostatic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57169994A JPS5959628A (en) | 1982-09-27 | 1982-09-27 | Carcinostatic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS5959628A true JPS5959628A (en) | 1984-04-05 |
Family
ID=15896618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57169994A Pending JPS5959628A (en) | 1982-09-27 | 1982-09-27 | Carcinostatic agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5959628A (en) |
-
1982
- 1982-09-27 JP JP57169994A patent/JPS5959628A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ghasemian et al. | Selenium nanoparticles stimulate growth, physiology, and gene expression to alleviate salt stress in Melissa officinalis | |
| HU228503B1 (en) | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation | |
| Khadrawy et al. | Protective effect of nanocurcumin against neurotoxicity induced by doxorubicin in rat’s brain | |
| EP1330258B1 (en) | Kahalalide f formulation | |
| JP2013035819A (en) | Drug and method for using the same | |
| CN105961385A (en) | Novel application of tea polyphenol for promoting corn seed germination under heavy metal stress, seed soaking liquid and germination method | |
| Kandadi et al. | Cardiac-specific catalase overexpression rescues anthrax lethal toxin-induced cardiac contractile dysfunction: role of oxidative stress and autophagy | |
| JPS5959628A (en) | Carcinostatic agent | |
| TW200425915A (en) | Selective cyclooxygenase-2 inhibitor patch | |
| JPH04103529A (en) | Carcinostatic agent | |
| AU659085B2 (en) | Method of treatment with HSP70 | |
| EP1789064A1 (en) | Improved anticancer treatment | |
| Labulo et al. | Modulation of physiological and biochemical activities of Eugenia uniflora by green-synthesized silver nanoparticle and melatonin under drought stress | |
| CN114667137A (en) | Approaches to coping with oxidative stress to modulate redox balance and prevent oxidative stress-induced cellular damage and death | |
| Chen et al. | Internal limiting membrane flap in the management of retinal detachment due to paracentral retinal breaks | |
| JP2016033163A (en) | Piroxicam-containing matrix patch, and method for local treatment of acute and chronic pain and inflammation using the same | |
| EP3145311B1 (en) | Biologically active synergistic composition | |
| Sehgal et al. | Geographical pattern of pemphigus in North India | |
| JPS58167510A (en) | Poultice containing indomethacin | |
| CN121100731B (en) | Regulation and control method for promoting branching efficiency of fruit trees | |
| CN106749134B (en) | Application of Benzofuran Compounds in Stimulating Insect Resistance of Plants | |
| CN114831138B (en) | Protective agent for preventing plant leaf sunburn and preparation method and application method thereof | |
| Street et al. | Occurrence of Riboflavin in Tubercle Bacillus. | |
| JPH04103532A (en) | Carcinostatic agent | |
| Selbo | Photochemical internalisation (PCI): a further development of photodynamic therapy for the treatment of skin cancer |